Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Annals of the Rheumatic Diseases 74.2 (2015): S. 415-421.
- Keyword
-
-
Orthopädie
- Event
-
Veröffentlichung
- (where)
-
Erlangen
- (who)
-
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
- (when)
-
2015
- Creator
-
Listing, Joachim
Kekow, Jörn
Manger, Bernhard
Burmester, Gerd-Rüdiger
Pattloch, Dagmar
Zink, Angela
Strangfeld, Anja
- URN
-
urn:nbn:de:bvb:29-opus4-78876
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:48 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Listing, Joachim
- Kekow, Jörn
- Manger, Bernhard
- Burmester, Gerd-Rüdiger
- Pattloch, Dagmar
- Zink, Angela
- Strangfeld, Anja
- Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
Time of origin
- 2015
Other Objects (12)
Seronegative and seropositive rheumatoid arthritis treated with rituximab
Local administration of glucocorticoids decreases synovial citrullination in rheumatoid arthritis
Glucocorticoids and endothelial function in inflammatory diseases: focus on rheumatoid arthritis
Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
TNFα modulates protein degradation pathways in rheumatoid arthritis synovial fibroblasts
Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
TCD4pos lymphocytosis in rheumatoid and psoriatic arthritis patients following TNFα blocking agents
Dynamic Characteristics and Predictive Profile of Glucocorticoids Withdrawal in Rheumatoid Arthritis Patients Commencing Glucocorticoids with csDMARD: A Real-World Experience
Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis
Posterior reversible encephalopathy syndrome: A rare complication of rituximab therapy in rheumatoid arthritis
Salivary TNFα levels in groups of subjects with rheumatoid arthritis and chronic periodontitis
Seronegative and seropositive rheumatoid arthritis treated with rituximab
Local administration of glucocorticoids decreases synovial citrullination in rheumatoid arthritis
Glucocorticoids and endothelial function in inflammatory diseases: focus on rheumatoid arthritis
Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
TNFα modulates protein degradation pathways in rheumatoid arthritis synovial fibroblasts
Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
TCD4pos lymphocytosis in rheumatoid and psoriatic arthritis patients following TNFα blocking agents
Dynamic Characteristics and Predictive Profile of Glucocorticoids Withdrawal in Rheumatoid Arthritis Patients Commencing Glucocorticoids with csDMARD: A Real-World Experience
Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis
Posterior reversible encephalopathy syndrome: A rare complication of rituximab therapy in rheumatoid arthritis
Salivary TNFα levels in groups of subjects with rheumatoid arthritis and chronic periodontitis
Seronegative and seropositive rheumatoid arthritis treated with rituximab
Local administration of glucocorticoids decreases synovial citrullination in rheumatoid arthritis
Glucocorticoids and endothelial function in inflammatory diseases: focus on rheumatoid arthritis
Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
TNFα modulates protein degradation pathways in rheumatoid arthritis synovial fibroblasts
Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
TCD4pos lymphocytosis in rheumatoid and psoriatic arthritis patients following TNFα blocking agents
Dynamic Characteristics and Predictive Profile of Glucocorticoids Withdrawal in Rheumatoid Arthritis Patients Commencing Glucocorticoids with csDMARD: A Real-World Experience
Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis
Posterior reversible encephalopathy syndrome: A rare complication of rituximab therapy in rheumatoid arthritis